Pfizer & others should be ashamed that they have raised drug prices for no reason.
President Trump tweeted.
They are merely taking advantage of the poor & others unable to defend themselves, while at the same time giving bargain basement prices to other countries in Europe & elsewhere.
We will respond!”
The list price remains unchanged for the majority of our medicines.
Our portfolio includes more than 400 medicines and vaccines;
we are modifying prices for approximately 10 percent of these, including some instances where we're decreasing the price,
a spokesperson for Pfizer emailed.
List prices do not reflect what most patients or insurance companies pay.
In the first quarter of 2018 the net selling price increase was 0 percent due to the growing amount of rebates paid back to stakeholders in the biopharmaceutical supply chain.
Just talked with Pfizer CEO and @SecAzar on our drug pricing blueprint. Pfizer is rolling back price hikes, so American patients don’t pay more. We applaud Pfizer for this decision and hope other companies do the same. Great news for the American people!
Of 107 physician advisers who voted on the committees 40 over a nearly 4-year period received more than $10,000 in post hoc earnings or research support from the makers of drugs that the panels voted to approve, or from competing firms; 26 of those gained more than $100,000; and seven more than $1 million.
Of the more than $26 million in personal payments or research support from industry to the 17 top-earning advisers―who received more than $300,000 each―94% came from the makers of drugs those advisers previously reviewed or from competitors.
Most of those top earners―and many others―received other funds from those same companies, concurrent with or in the year before their advisory service.